JOYCLU combines hyaluronic acid and an anti-inflammatory drug, chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint, and is approved to treat osteoarthritis of the knee and hip via single injection once every four weeks.
Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered to be low.
JOYCLU combines hyaluronic acid and an anti-inflammatory drug, chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint, and is approved to treat osteoarthritis of the knee and hip via single injection once every four weeks.
Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered to be low.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
